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 Ionizing radiation is a known risk factor for malignant
neoplasms, including sarcomas.
 The increasing use of Autologous Fat Transfer in breast
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 The regenerative effects of Autologous Fat Transfer are
based on the same hormones, growth factors and stem
cells that stimulate neoplastic angiogenesis and cancer
progression.
 One must consider a possible synergism between radio-
therapy and Autologous Fat Transfer that promote
tumour growth.Dear editor,
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue
sarcoma involving dermis, subcutaneous fat, and rarely fascia/mus-
cle. Such tumours are locally aggressive, marked by high local
recurrence rates and low metastatic potential [1]. DFSP may arise
within surgical scars, old burns, previous traumatic injuries, radia-
tion dermatitis, vaccinations, central venous line puncture sites,
and even insect bites. Herein, we describe a patient with post-
mastectomy DFSP occurring after breast irradiation and reconstruc-
tion by autologous fat transfer (AFT).
A 53-year-old womanwas diagnosed with breast mucinous car-
cinoma on November 2014 (Fig. 1). Magnetic resonance imaging
confirmed a right breast tumour of outer quadrants and an axillary
mass. Ultrasound e guided axillary fine-needle aspiration provided
a cytological diagnosis of metastatic breast cancer. The patient
received neoadjuvant chemotherapy (paclitaxel, adriamycin, cyclo-
phosphamide) and in January 2015 underwent nipple-sparingmas-
tectomy with axillary lymph node dissection. Given the limited
volume of contralateral breast, multistage fat grafting was the cho-
sen means of reconstruction. The first lipoinjection was performed
at the time of mastectomy; 180 g of fat were introduced into Pector-
alis Major muscle. Radiotherapy (50 Gy in 25 fractions of 2 Gy over
5 weeks) was then delivered, during March and April 2015, to the
chest wall and the supraclavicular lymph nodes (Fig. 2). Between
2015 and 2018, six fat grafting procedures (230 g, 200 g, 195 g,
210 g, 160 g, and 170 g, respectively) took place, completing the
reconstruction (Fig. 3); the fat tissue was injected subcutaneously,
in front of the Pectoralis Major muscle, in all quadrants of the right
breast. The entire postoperative course was uneventful. The patient
returned in September 2019 with a lump beneath the skin of upper
right breast that had enlarged in the preceding 4 months. She de-
nied any recent weight loss, fever, night sweats, or chills. Bye Society for Regenerative
ative Medicine. Production and hophysical examination, a firm but painless mass (2.5 cm) was
detected, unaccompanied by heat or redness. An incisional biopsy
was performed. In sections stained with hematoxylin and eosin,
the highly proliferative spindle-shaped cells characteristic of DFSP
were identified. Plain chest X-ray and ultrasonography of abdomen
and regional lymph nodes were clear. In December 2019, the massFig. 1. Pre-mastectomy picture.
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Fig. 2. Two weeks after term of radiotherapy. This last was delivered to the right chest
wall and the supraclavicular lymphnodes.
Fig. 3. Final result six months after seventh fat grafting session. Red cross indicates the
location of DFSP.
Fig. 4. Surgical excision of DFSP with 3 cm-safe margin.
Fig. 5. Histologic appearance of DFSP: low-power view (H&E stain 2X) of tumor cells
(A); high magnification (H&E stain 40X) shows spindle-shaped tumor cells arranged in
irregular intertwining bands (B). Immunohistochemistry of the tumor cells (magnifi-
cation 40X) showing diffuse positivity for CD34 (C).
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muscular fascia (Fig. 4). The defect was covered by a partial-
thickness skin graft. Tissue examination revealed multiple foci of
DFSP deep within dermis. Immunohistochemical stains were posi-
tive for Vimentin and CD34 (Fig. 5). Ki-67 positivity was at 25%.
Three months after excision, no local recurrence or metastasis
was evident.
AFT has become increasingly common for breast reconstruc-
tions or other reasons [2]; advantages include no risk of rejection,
relative abundance of adipose tissue in most patients, ease of
obtaining fat by lipoaspiration, minimal donor-site morbidity.
There is an increasing belief that fat grafting under radiated skin
can reverse the damage caused by radiotherapy. These clinical ben-
efits were attributed to the regenerative properties of undifferenti-
ated multi-potent adipose tissue-derived stem cells (ADSCs) within
the stromal vascular fraction (SVF) of lipoaspirate [3]. ADSCs are
able to secrete multiple growth factors (GFs) including platelet-derived growth factor (PDGF), vascular endothelial growth factor
(VEGF), insulin-like growth factor 1 (IGF-1), hepatocyte growth fac-
tor (HGF), and transforming growth factor (TGF)-b. This last plays a
central role in tumor suppression and yet, paradoxically, in tumor
promotion. Concerning molecular signals implicated in the patho-
genesis of radiotherapy-injury, up-regulation of the TGF-b signaling
is a mechanism common to numerous conditions of pathological
fibrosis [4]. Radiotherapy, particularly associated with surgery, cre-
ates tissue hypoxia. ADSCs’ secretion of aforementioned pro-
angiogenetic, anti-apoptotic and immunomodulatory growth fac-
tors is useful to increase blood supply in poorly vascularized tissues,
but at the same time can promote malignant transformation and
cancer progression. ADSCs are indeed able to affect the epithelial
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progression determines the shift of the tumour toward amore inva-
sive phenotype [5]. The effects of ADSCs on EMTand cellular migra-
tion aremediated, among other, by theWnt pathway. There is also a
reverse influence, as breast tumor-derived factors are able to pro-
mote ADSCs transformation into tumor-associated fibroblasts,
through the inhibition of Wnt-signaling [6]. As aforementioned,
ADSCs release TGF-b, which is responsible for collagen deposition
and extra-cellular matrix remodeling. However, TGF-b secretion
promote EMT in cancer cells. Parallelly, TGF-b signaling is able to
induce myofibroblastic differentiation in ADSCs exposed to breast
cancer exosomes, thus promoting desmoplastic transformation of
the tumor microenvironment [7]. In earlier reports, DFSP plausible
aetiologies are largely ignored. It is reasonable to question whether
fat grafting played a role in predisposing to DFSP. The cellular origin
of soft tissue sarcomas is not fully understood. According to “cancer
stem cell hypothesis”, tumours originate from the malignant trans-
formation of stem cells; it is true that multipotent stem cells can
differentiate into diverse cellular lineages and can be recruited to
areas of severe tissue injury, but in some settings they may also
initiate malignant transformation. Nowadays, the original belief
that tumours might originate from the malignant transformation
of their tissue-specific stem cells is largely abandoned. It was
observed that ADSCs may represent potential initiating cells of ma-
lignancy, including soft tissue sarcomas. Chen et al. [8] treated
ADSCs from mice with 3-methycholanthrene, a potent carcinogen.
The resultant transformed ADSCs were then injected subcutane-
ously into immunocompromised mice; they found that they gener-
ated several types of soft tissue sarcomas (synovial sarcoma,
malignant fibrous histiocytoma, fibrosarcoma). Oncological con-
cerns have been raised regarding the use of AFT in patients with
previous breast cancer. Currently, there is no clinical evidence of
oncologic risk associated with fat grafting [9]. Sarcomas, on the
other hand, are biologically quite different from breast carcinoma.
An unexpected local recurrence of osteosarcoma, 13 years after
definitive surgery and 18 months after lipofilling, caused Perrot
et al. [10] to pursue a possible link. Using preclinical models of os-
teosarcoma, they ultimately demonstrated that fat grafts or pro-
genitor cells were capable of promoting tumour growth. Pennati
et al. [11] gauged the oncologic safety of fat grafting in patient
with sarcomas, including seven cases with DFSP. Two lesions
recurred locally prior to fat grafting, none developing thereafter.
Having observed no heightened risk of malignancy, they still sug-
gested a pause of at least 12months between last oncologic surgery
and procedures of this type. Also ionizing radiation is known to
induce various malignant neoplasms [12], including sarcomas.
The following features generally apply to post-radiation soft tissue
sarcomas: (i) history of prior irradiation, (ii) origination in field of
radiation, (iii) 2-year minimum latency from radio exposure to
onset, (iv) histopathology unlike that of irradiated antecedent. All
stipulations above applied to our patient. McLoughlin et al. [13]
were the first to chronicle post-radiation DFSP, but cases published
since then have been scarce [14e17]. The pathogenesis of radiation-
induced soft tissue sarcomas has yet to be fully explained. Meehan
& LeBoit [18] examined a possible correlation between spindle cells
of DFSP and radiation fibroblasts, as hallmarks of chronic radiation
dermatitis. Based on their immunohistochemical analysis, it ap-
pears the two are unrelated. Aiba et al. [19] also examined CD34
expression by various fibrohistiocytic tumours, discovering that
DFSP is unique in this regard. In normal tissues, CD34-positive den-
dritic cells surround blood vessels, nerves, hair follicles, and sweat
glands; and circulating intravascular fibroblast-like cells (fibro-
cytes), staining positive for CD34 and Vimentin, have been reported
[20]. These cells comprise a subpopulation of leukocytes that
mediate tissue repair. Ostensibly, direct irradiation or long-termstimulation by cytokines, especially transforming growth factor
(TGF)-b secreted by radiation-damaged tissues [10], may trigger
their malignant transformation. Studies have shown that DFSP
demonstrates the chromosomal translocation t (17; 22) (q22;
q13) between chromosome 17 and chromosome 22. This transloca-
tion results in the collagen 1A1 (COL1A1) gene from chromosome
17 fusing with the platelet-derived growth factor (PDGF)-b gene
on chromosome 22. COL1A1 encodes a major component of type
1 collagen, the most abundant collagen in humans. PDGFb is a tyro-
sine kinase that acts as a growth factor for connective tissue cells,
normally under negative control. The gene rearrangement upregu-
lates PDGFb, resulting in overproduction of PDGF, continuous auto-
crine activation of PDGF receptor (PDGFR)-b, cellular proliferation
and tumour formation. Kikuchi et al. [21] established fibroblast-
like cell strains from DFSP and investigated their response to
various growth factors, including PDGF, compared with normal fi-
broblasts. They found increased expression of PDGFb receptors in
DFSP cells; they did not observe spontaneous production of PDGF
protein in the cytoplasmic extracts of normal fibroblasts or DFSP
cells, suggesting that TGF-b, which is also known as an inducer of
PDGF-like peptides in fibroblasts, could induce the expression of
PDGF-like peptides on tumour cells in vivo. Finally, because the first
lipoinjection in our patient was prior to radiotheraphy, one must
consider the effects of radiotherapy on adipose tissue. Can radio-
therapy induce malignant transformation in mesenchymal stem
cells? Recent findings suggest that ADSCs display radio-resistance
compared with other components of SVF. This may be explained
by a greater ability of mesenchymal stem cells to retain their prolif-
erative capacity due to superior DNA damage repair mechanisms,
compared with those found in terminally differentiated cells. Addi-
tionally, reduced metabolic demands of steady-state ADSCs may
protect them from hypoxia and subsequent apoptosis, enabling
their preservation [22]. Although mesenchymal stem cells are
radio-resistant in terms of cellular survival, radiotherapymay result
in irreversible injury in terms of the potential for cellular differen-
tiation, as observed by Sch€onmeyr et al. [23]. On the other hand,
Christensen et al. [24] described how bone marrow-derived human
mesenchymal stem cells were capable of exhibiting a malignant
phenotype when irradiated with a low (2.5 Gy) and a high
(15 Gy) dose of gamma-rays and followed for up to 6 months after
radiation. Inoculation of the transformed mesenchymal stem cells
on immunocompromised mice resulted in tumours of primitive
mesenchymal origin. It is very complex to trace the exact origin
of DFSP in this patient; we are not able to ascribe it to radiotherapy
only rather than AFT only, or a possible synergic action of both, but
the events that transpired underscore a need for additional studies.
We also acknowledge the limitation of a 3-month follow-up,
presuming a 3-year window for recurrent disease. Long-term
monitoring of these patients is imperative.
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